Histochemical androgen binding assay in prostatic cancer

A group of 60 patients with clinical stage C or D prostatic carcinoma was evaluated for androgen binding using a histochemical assay. Of the patients positive for binding 82 per cent either responded to hormonal therapy or remained stable, while 100 per cent of those negative for binding had progression. Of 6 men whose cancer was considered borderline positive 2 manifested a partial clinical response, while 4 had progression.